ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

Clinical trial NCT07472322 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07472322
Sponsor: University of Wisconsin, Madison
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Merkel Cell Carcinoma Merkel Cell Carcinoma, Stage III Merkel Cell Carcinoma, Stage IV

Start date: 2026-08-01
Primary completion: 2031-05-01
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.